FDA communicated eligibility for accelerated approval for ProKidney Corp., which plans to present study results at ASN.
Steady: 1 development in the last 24 hours, 1 in the last 7 days
Updated 1 hour ago
The latest in this situation
How it started
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA communicated eligibility for accelerated approval for ProKidney Corp., which plans to present study results at ASN.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.ProKidney is advancing its Phase 3 PROACT 1 study.1 source
- ProKidney Corp. received RMAT designation from the FDA and filed a Current Report on Form 8-K with the SEC.Sub-event
FDA granted eligibility for accelerated approval for ProKidney Corp.1 source
ProKidney's Rilparencel received RMAT designation from the FDA.1 source
Keep exploring
The entities involved
Related events
- Arise is seeking FDA approval for a drug as of October 7, 2026.
- FDA and Pfizer are seeking regulatory approval for their products.
- FDA approval enables commercial availability for a product associated with Indianapolis.
- Eli Lilly and Company plans to submit a drug candidate to the FDA for review and approval.
- FDA approval expands patient access to therapies for ACCORD.
Coverage
Newest first; wire copies grouped- manilatimes.net
- ZacksPROK Surges More Than 500% on Upbeat Data From Kidney Cell Therapy Study Shares of ProKidney Corp. PROK skyrocketed 515% yesterday after the company reported encouraging top-line data from the phase
- GlobeNewswireProKidney to Participate in the H.C. Wainwright 4th Annual Kidney Virtual Conference WINSTON-SALEM, N.C., July 09, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company
- Unknown outlet